Planegg/Martinsried (pta/10/16/2023/14:00 UTC+2)
Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focused on the discovery and development of T-cell immunotherapies for solid tumors, will be presented at the ESMO Congress, to be held starting in 2019. Poster presentation will be held From 20 to 24 October 2023 in Madrid, Spain.
The data to be presented show that T-cell receptors (TCRs) with optimized affinity for Medigene’s PD1-41BB costimulatory switch protein (CSP) provide robust T-cell receptor (TCR)-modulated T cell protection against a variety of different mechanisms. of immunosuppression provided by the microenvironment of solid tumors. These include CSP-enhanced polycytokine secretion, proliferation, and protection from TCR T cell exhaustion in vitro.
The full summary of this research is: here Published online.
Details about poster display:
Summary and title:Alleviating immunosuppression by the tumor microenvironment using the PD1-41BB switch protein with optimized affinity for TCRs for first-line and third-generation TCR-T therapies.”
Final label number: 2249 p
Date/Time: Saturday 21 October 2023, lunchtime poster session from 12pm to 1pm CEST, poster exhibition from 9am to 6:30pm CEST
category: Translational research (agnostic)
—End of press release—
About Medigen AG
Medigene AG (FWB: MDG1) is an immuno-oncology company that specializes in developing T-cell therapies to effectively combat cancer. The company’s comprehensive technology platform, built on numerous proprietary and exclusive TCR generation, optimization and product optimization technologies, allows Medigene to deliver first-in-class TCR-modulated differentiated T-cell therapies for many conditions. Solid tumor indications that are optimized for safety, efficacy and durability. This platform offers product candidates for both its own treatment lines and for partnerships. More information at www.medigene.de
This announcement contains certain forward-looking statements. These reflect Medigene’s views as of the date of this communication. Medigene’s actual results may differ materially from the results expressed in the forward-looking statements. Medigene is under no obligation to update forward-looking statements. Medigene® is a trademark of Medigene AG. This trademark may be owned or licensed in specific countries.
For reasons of readability, no gender distinction has been made. The corresponding terms apply to both sexes in the spirit of equal treatment.
Tel: +49 89 2000 3333 01
If you no longer wish to receive information about Medigene in the future, please notify us by email ([email protected]) and we will then remove you from our distribution list.
“Total coffee aficionado. Travel buff. Music ninja. Bacon nerd. Beeraholic.”